Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study to assess the efficacy and safety of front-line combination of dasatinib (SPRYCEL®) and pegylated-interferon alpha 2b (Peg-IFNα2b) therapy in patients newly diagnosed with chronic phase chronic myeloid leukaemia (CP-CML)

Trial Profile

A phase II study to assess the efficacy and safety of front-line combination of dasatinib (SPRYCEL®) and pegylated-interferon alpha 2b (Peg-IFNα2b) therapy in patients newly diagnosed with chronic phase chronic myeloid leukaemia (CP-CML)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Peginterferon alfa-2b
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms DASA-PEGIFN
  • Most Recent Events

    • 08 Dec 2015 Preliminary results (n=81) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 26 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top